MOTCO’s Acceleron Pharma XLRN Stock Holding History

MOTCO’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-75	Closed	-$3K	–	668
2016 Q3	$3K	Buy	+75	New	+$2.48K	﹤0.01%	585

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

MOTCO's XLRN Position: Q4 2016 in Review

MOTCO sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 75 shares — an estimated $3K sold.

MOTCO first reported a position in XLRN in Q3 2016 and held it in 1 quarter. The position peaked at $3K in Q3 2016. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

MOTCO reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
MOTCO sold 75 Acceleron Pharma shares in Q4 2016, an estimated $3K.
MOTCO first reported a position in Acceleron Pharma in Q3 2016 and held it in 1 quarter.
MOTCO's Acceleron Pharma position peaked at $3K in Q3 2016.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on MOTCO's 13F filing for Q4 2016, filed 10 Feb 2017.